Clin2
NCT07362446Worth exploringRecruiting

Study of a heart drug for first-time heart attack patients

Myocardial InfarctionReperfusion InjuryAMISTEMI (ST Elevation MI)

Part of Heart & circulation clinical trials.

This trial tests a new drug given shortly after a first heart attack to see if it can reduce heart damage when blood flow is restored. It is for patients having a specific type of heart attack (STEMI) and getting a procedure to open the blocked artery within 6 hours of symptoms starting.

Summary written for real people, not researchers, by Clin2.

Phase
Phase 2
Enrollment
300 people
Ages
40 years to 75 years
Study type
Interventional

Who can take part

  • You are having your first heart attack (a type called STEMI that shows on an EKG).
  • You are scheduled for a procedure to open the blocked artery (angioplasty or PCI) within 6 hours of symptoms starting, and doctors expect to start the procedure in less than 2 hours after you arrive at the hospital.
  • You are a man between 40 and 75 years old, or a woman between 55 and 75, or a woman 40–55 who cannot become pregnant.
  • Your blood pressure, heart rate, and oxygen levels must be stable, and you must be in Killip class I or II (meaning your heart failure symptoms are mild or none).
  • You must not have had a heart attack or major heart surgery before, and you cannot have certain conditions that would make an MRI or the study drug unsafe (like kidney problems, pacemaker, or allergy to soy or egg).
  • If you are a man with a partner who could become pregnant, you must agree to use effective birth control for at least 7 days after receiving the study drug.

View the official record on ClinicalTrials.gov

Quick eligibility check

Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.

Similar studies

Other trials that look related to this one.

NCT07380919Recruiting· Phase 2/Phase 3
Study of ranolazine to prevent heart muscle damage after a heart attack

This trial tests whether a medication called ranolazine can help prevent damage to tiny blood vessels in the heart after a certain type of heart attack (STEMI). You may be eligible if you recently had this kind of heart attack and had a successful procedure to open a blocked artery, but still have other blockages that can be treated with stents.

Catanzaro, Italy
NCT05880355Not yet recruiting· Early Phase 1
Imaging study after heart attack to guide new treatments

This early research study uses heart and blood-vessel imaging soon after a heart attack to better understand how new therapies might affect blood vessels. You may be asked to have imaging tests and possibly take study medicines, depending on what your doctor finds and your health status.

Charlottesville, Virginia
NCT06227754Recruiting
OCT vs. angiography for heart attack treatment

This trial compares two ways to guide treatment during a heart attack: using a special camera (OCT) inside the artery or standard X-ray (angiography). It aims to see which method leads to better results for patients.

Daegu, Daegu
NCT06935383Not yet recruiting· Phase 2
Treating microvessel injury after heart attack

This trial tests treatments for small blood vessel damage after a major heart attack (STEMI). If you have had a heart attack and are receiving a stent, this study may help improve recovery by targeting microvascular injury.

NCT03998319Recruiting· Phase 3
Testing low-dose clot-busting drug after heart attack stent

This trial tests whether a low-dose clot-busting medicine placed into the heart artery after a primary stent can improve outcomes in people with a certain type of heart attack. It also involves short hospital follow-ups and a heart MRI to look at how the heart is recovering.

Bankstown, New South Wales
NCT06465303Recruiting· Phase 2
Study of RTP-026 for heart attack patients

This trial tests a new medicine called RTP-026 for people having a serious heart attack (STEMI). It looks at whether the medicine is safe and helps the heart recover better when given along with the standard procedure to open the blocked artery.

Copenhagen

Hear when a new Reperfusion Injury trial opens

We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.